On January 10, 2020 IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the decryption of the human genome, which performs interpretable genomic analyzes for academic and private laboratories, reported its unaudited business figures for the year 2019 (Press release, Integragen, JAN 10, 2020, View Source [SID1234552965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019.

The growth in sales is linked to the partnership with the Groupement Coopératif de Santé (GCS) SeqOIA, in which IntegraGen operates the sequencing platform, as well as the good performance of all business lines, in particular the sequencing platform in microbiology operated for the Institut Pasteur.

Sales of software and consulting services continued to grow, reaching €0.6 million over the whole year.

Cash balance was at the end of 2019 was € 2.8m, up €200k compared to June 30, thanks to positive operating cash flows in the second half.

2020 OUTLOOK: CONTINUED SUSTAINED DYNAMIC GROWTH
Commercial momentum will continue in 2020 given the multi-year contracts in place and the increase in order intake for sequencing services activity. Revenues in the genomic data interpretation tools segment should also increase significantly in 2020.

Bernard Courtieu, Chairman and CEO of IntegraGen, stated "The 20% increase in our revenues in 2019, which reflects the good momentum of all of our offers (sequencing services, platform operations services for most prestigious institutions and interpretation software), and our efforts to optimize the Clinical Genomics Experts 2/2 economic model, enabling us to generate a positive cash flow during the second half of the year. We reiterate our confidence in the prospects for profitable growth for 2020."

The financial results for 2019 will be published on April 3, 2020 (before the financial markets open).